The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.
复制标题
DOI：
10.3324/haematol.2017.186577
复制
发表时间：
2018-07
期刊：
影响因子：
10.1
通讯作者：
International T-cell Project Network
中科院分区：
文献类型：
--
作者：
Bellei M;Foss FM;Shustov AR;Horwitz SM;Marcheselli L;Kim WS;Cabrera ME;Dlouhy I;Nagler A;Advani RH;Pesce EA;Ko YH;Martinez V;Montoto S;Chiattone C;Moskowitz A;Spina M;Biasoli I;Manni M;Federico M;International T-cell Project Network
本分析探讨了影响参加前瞻性国际T细胞项目的原发性难治性和复发性外周T细胞淋巴瘤患者生存率的因素。我们分析了2006年9月至2015年12月期间入组的1020例新诊断疾病患者的数据。在接受一线治疗的937例患者中，436例（47%）被确定为难治性，197例（21%）为复发性。从治疗结束到复发的中位时间为8个月（范围2-73）。总体而言，75例患者（8%）接受了骨髓移植，包括12例难治性和22例复发性患者。在记录难治性/复发性疾病后中位随访38个月（范围1-96个月）后，440名患者死亡。中位总生存期（OS）为5.8个月，3年总生存率在难治性和复发性患者中分别为21%和28%（P<0.001）。接受或未接受挽救性骨髓移植的患者3年生存率分别为48%和18%（P<0.001）。在单变量考克斯回归分析中，难治性疾病与更高的死亡风险相关（HR=1.43，P=0.001），而晚期复发（>12个月，HR 0.57，P=0.001）和移植挽救治疗（HR=0.36，P<0.001）与更好的OS相关。组织学方面没有发现OS差异。这项研究准确地反映了根据全球护理标准治疗的患者的结局。结果证实，外周T细胞淋巴瘤患者复发或进展后预后差。对于化疗敏感性疾病，12个月以上复发的患者，巩固骨髓移植可能有益。
This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation.
登录
查看更多内容
影响因子：
45.3
作者：
Vose, Julie M.;Neumann, M.;Harris, Mildred E.
通讯作者：
Harris, Mildred E.
影响因子：
45.3
作者：
Mak, Vivien;Hamm, Jeremey;Savage, Kerry J.
通讯作者：
Savage, Kerry J.
影响因子：
3.3
作者：
Biasoli, Irene;Cesaretti, Marina;Luminari, Stefano
通讯作者：
Luminari, Stefano
DOI：
10.1590/s1516-84842009000800007
发表时间：
2009-08-01
影响因子：
--
作者：
Federico, Massimo;Bellei, Monica;Vose, Julie M.
通讯作者：
Vose, Julie M.
影响因子：
11.5
作者：
O'Connor, Owen A.;Bhagat, Govind;Bates, Susan E.
通讯作者：
Bates, Susan E.